Effectiveness of orally administered co-enzyme Q10 for schizophrenia: cognitive, functional and biochemical outcomes from a double blind, randomised, placebo controlled trial

Hargreaves, April, Maguire, Áine, Mooney, Christina, Hargreaves, Iain, Heaton, Robert, Philips, Suzannah and Gill, Michael (2020) Effectiveness of orally administered co-enzyme Q10 for schizophrenia: cognitive, functional and biochemical outcomes from a double blind, randomised, placebo controlled trial. Schizophrenia Bulletin, 46 (Supp 1). S253. ISSN 1745-1701

Full text not available from this repository.

Abstract

Coenzyme Q10 (CoQ10) is an endogenous compound that is essential for energy production within the mitochondria and also functions as a potent anti-oxidant, inhibiting oxidative stress and damage. Often deficits in CoQ10 are associated with fatigue, and cognitive and psychological impairment. In light of its many functions, CoQ10 supplementation to minimise decline and improve symptoms has been investigated in multiple disorders including neurological and neuropsychiatric disorders, with results indicating positive effects on fatigue, cognitive impairment and affective difficulties for disorders such as bipolar disorder and chronic fatigue syndrome. There is also evidence of mitochondrial dysfunction in schizophrenia. In light of this evidence, the current study aimed to investigate the potential effect of CoQ10 supplementation on 1) cognitive function and 2) psychological and physical health in schizophrenia and schizoaffective disorder.

Item Type:	Article
Subjects:	B Philosophy. Psychology. Religion > Psychology B Philosophy. Psychology. Religion > Psychology > Cognitive psychology R Medicine > RA Public aspects of medicine > RA790 Mental Health
Divisions:	School of Business > Staff Research and Publications
Depositing User:	Dan English
Date Deposited:	25 Sep 2020 09:15
Last Modified:	25 Sep 2020 09:15
URI:	https://norma.ncirl.ie/id/eprint/4341

Actions (login required)

View Item